MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/jc.2009-0747

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2009

Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.

Träisk Frank, Tallstedt Leif, Abraham-Nordling Mirna, Andersson Tommy, Berg Gertrud, Calissendorff Jan, Hallengren Bengt, Hedner Pavo, Lantz Mikael, Nyström Ernst, Ponjavic Vesna, Taube Adam, Törring Ove, Wallin Göran, Asman Peter, Lundell Göran, Thyroid Study Group of TT 96

Сравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

CONTEXT: Previous randomized trials have suggested an association between radioiodine treatment for Graves' hyperthyroidism and thyroid-associated ophthalmopathy (TAO).

OBJECTIVES

The aim of the study was to compare the occurrence of worsening or development of TAO in patients who were treated with radioiodine or antithyroid drugs.

DESIGN

We conducted a randomized trial (TT 96) with a follow-up of 4 yr. PATIENTS, SETTING, AND INTERVENTION: Patients with a recent diagnosis of Graves' hyperthyroidism were randomized to treatment with iodine-131 (163 patients) or 18 months of medical treatment (150 patients). Early substitution with T(4) was given in both groups.

MAIN OUTCOME MEASURE: Worsening or development of TAO was significantly more common in the iodine-131 treatment group (63 patients; 38.7%) compared with the medical treatment group (32 patients; 21.3%) (P < 0.001).

RESULTS

The risk for de novo development of TAO was greater in patients treated with iodine-131 (53 patients) than with medical treatment (23 patients). However, worsening of TAO in the 41 patients who had ophthalmopathy already before the start of treatment was not more common in the radioiodine group (10 patients) than in the medical group (nine patients). Smoking was shown to influence the risk of worsening or development of TAO, and smokers treated with radioiodine had the overall highest risk for TAO. However, in the group of smokers, worsening or development of TAO was not significantly associated with the choice of treatment for hyperthyroidism.

CONCLUSIONS

Radioiodine treatment is a significant risk factor for development of TAO in Graves' hyperthyroidism. Smokers run the highest risk for worsening or development of TAO irrespective of treatment modality.

Для цитирования: Träisk Frank, Tallstedt Leif, Abraham-Nordling Mirna, Andersson Tommy, Berg Gertrud, Calissendorff Jan, Hallengren Bengt, Hedner Pavo, Lantz Mikael, Nyström Ernst, Ponjavic Vesna, Taube Adam, Törring Ove, Wallin Göran, Asman Peter, Lundell Göran, Thyroid Study Group of TT 96. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.. The Journal of clinical endocrinology and metabolism. 2009. DOI: 10.1210/jc.2009-0747.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.